Prospects for CV Risk Factor Reduction with PCSK9 and CEPT Inhibitor Therapies - A. Michael Lincoff, MD

↳ This is a section part of Moment: CRT 2015 Atherosclerosis & Research - Atherosclerosis & Lipid Management

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$20.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Prospects for CV Risk Factor Reduction with PCSK9 and CEPT Inhibitor Therapies presented by A. Michael Lincoff, MD at CRT 2015

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$20.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

Interventional Cardiologists
Interventional Fellows
Physiology technicians
Nurses and other allied healthcare professionals
Imaging Specialists
Radiologists

Session Name: Atherosclerosis & Lipid Management

Track: Atherosclerosis & Research

Learning Objectives

The latest updates in Atherosclerosis & Research

Other Components in this Moment

Optimization of Lipid Parameters - Evan A. Stein, MD, PhD

Update on HDL Infusions and Atherosclerosis Regression in the ACS Patient - H. Bryan Brewer Jr., MD

Ezetimibe: From Drug Development to IMPROVIT - Harry R Davis Jr., PhD

Recent Developments with Lipoprotein-Associated Phospholipase A2 Inhibitors - Robert L. Wilensky, MD

Prospects for CV Risk Factor Reduction with PCSK9 and CEPT Inhibitor Therapies - A. Michael Lincoff, MD

Update on the Role of PCSK9 in the Treatment of the High-Risk CVD Patient - Evan A. Stein, MD, PhD

LDL Reduction By PCSK9 Inhibition / Alirocumab - Dean J Kereiakes, MD

Are Triglycerides a Biomarker or Risk Factor in CVD? - Allen J. Taylor, MD

Is HDL a Biomarker or Risk Factor for CVD? - H. Bryan Brewer Jr., MD

Update on Clinical Trials with Novel CETP Inhibitors to Raise HDL: Where Are We Today? - H. Bryan Brewer Jr., MD

Loading Simple Education